A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Role of the pineal gland in immunity

1986 • 409 citations

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

1990 • 296 citations

Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies.

1983 • 194 citations

The Neuroendocrine Effects of Interleukin-2 Treatment

1989 • 140 citations

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.

1991 • 120 citations

Suppressor Cells in Neoplastic Disease

1978 • 93 citations

Cancer, cytokines, and cytotoxic cells: Interleukin-2 in the immunotherapy of human neoplasms

1990 • 86 citations

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2

1991 • 69 citations

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies

1989 • 46 citations

Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results

1993 • 42 citations

Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.

1992 • 39 citations

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

1991 • 39 citations

Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.

1990 • 29 citations